Eqis Capital Management Has Trimmed Abiomed (ABMD) Stake; Mgic Investment Wis (MTG) Shorts Up By 7.03%

January 24, 2018 - By John Hoffman

Eqis Capital Management Inc decreased Abiomed Inc (ABMD) stake by 48.58% reported in 2017Q3 SEC filing. Eqis Capital Management Inc sold 2,001 shares as Abiomed Inc (ABMD)’s stock rose 15.32%. The Eqis Capital Management Inc holds 2,118 shares with $357,000 value, down from 4,119 last quarter. Abiomed Inc now has $10.18 billion valuation. The stock increased 0.92% or $2.09 during the last trading session, reaching $230.27. About 231,505 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 40.97% since January 24, 2017 and is uptrending. It has outperformed by 24.27% the S&P500.

Mgic Investment Corporation Wis (NYSE:MTG) had an increase of 7.03% in short interest. MTG’s SI was 5.55M shares in January as released by FINRA. Its up 7.03% from 5.18 million shares previously. With 2.25M avg volume, 3 days are for Mgic Investment Corporation Wis (NYSE:MTG)’s short sellers to cover MTG’s short positions. The SI to Mgic Investment Corporation Wis’s float is 1.65%. It closed at $15.81 lastly. It is down 60.12% since January 24, 2017 and is uptrending. It has outperformed by 43.42% the S&P500.

MGIC Investment Corporation, through its subsidiaries, provides private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States. The company has market cap of $5.86 billion. The firm offers primary mortgage insurance that provides mortgage default protection on individual loans, as well as covers unpaid loan principal, delinquent interest, and various expenses associated with the default and subsequent foreclosure. It has a 16.71 P/E ratio. It also provides contract underwriting services; and other services for the mortgage finance industry, such as analysis of loan originations and portfolios, and mortgage lead generation services, as well as reinsurance arrangements.

Investors sentiment increased to 1.15 in Q3 2017. Its up 0.07, from 1.08 in 2017Q2. It increased, as 20 investors sold MGIC Investment Corporation shares while 89 reduced holdings. 37 funds opened positions while 88 raised stakes. 333.10 million shares or 3.73% more from 321.13 million shares in 2017Q2 were reported. Cim Inv Mangement, a Pennsylvania-based fund reported 37,567 shares. Hillsdale invested in 0.24% or 112,300 shares. Sei Invests has invested 0.01% in MGIC Investment Corporation (NYSE:MTG). Renaissance Lc accumulated 0.07% or 4.78M shares. Gotham Asset Mngmt Limited Liability Corporation stated it has 21,406 shares. Moore Mngmt L P stated it has 1.40 million shares or 0.34% of all its holdings. Proshare Advsrs stated it has 76,527 shares. Legg Mason Asset Mngmt (Japan) Comm Ltd has invested 0.77% in MGIC Investment Corporation (NYSE:MTG). 45,836 were accumulated by Tower Research Limited Liability Corporation (Trc). Metropolitan Life Insur Ny reported 249,091 shares. James Investment Research has invested 0.08% in MGIC Investment Corporation (NYSE:MTG). Moreover, Salem Invest Counselors has 0% invested in MGIC Investment Corporation (NYSE:MTG). Swiss Fincl Bank has invested 0.01% of its portfolio in MGIC Investment Corporation (NYSE:MTG). Vaughan Nelson Limited Partnership invested in 0.31% or 2.12M shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 13,009 shares.

Among 13 analysts covering MGIC Investment Corp. (NYSE:MTG), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. MGIC Investment Corp. has $20.0 highest and $7 lowest target. $15.54’s average target is -1.71% below currents $15.81 stock price. MGIC Investment Corp. had 41 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by M Partners with “Buy” on Tuesday, August 25. On Friday, November 3 the stock rating was downgraded by Deutsche Bank to “Hold”. Deutsche Bank upgraded the shares of MTG in report on Monday, December 12 to “Buy” rating. On Thursday, July 20 the stock rating was maintained by FBR Capital with “Buy”. The rating was maintained by Credit Suisse on Monday, May 2 with “Neutral”. As per Monday, February 13, the company rating was maintained by FBR Capital. The company was maintained on Thursday, October 19 by Keefe Bruyette & Woods. Deutsche Bank maintained the shares of MTG in report on Friday, July 21 with “Buy” rating. As per Wednesday, July 20, the company rating was maintained by FBR Capital. The firm has “Outperform” rating given on Thursday, June 30 by FBR Capital.

Analysts await ABIOMED, Inc. (NASDAQ:ABMD) to report earnings on January, 25. They expect $0.50 EPS, up 47.06% or $0.16 from last year’s $0.34 per share. ABMD’s profit will be $22.11 million for 115.14 P/E if the $0.50 EPS becomes a reality. After $0.44 actual EPS reported by ABIOMED, Inc. for the previous quarter, Wall Street now forecasts 13.64% EPS growth.

Since July 31, 2017, it had 0 insider purchases, and 5 sales for $9.51 million activity. ROSE ERIC A MD sold 982 shares worth $142,554. THOMAS PAUL also sold $1.55M worth of ABIOMED, Inc. (NASDAQ:ABMD) shares. $2.44M worth of ABIOMED, Inc. (NASDAQ:ABMD) was sold by Weber David M on Monday, July 31. On Saturday, September 30 the insider Greenfield Andrew J sold $1.91 million.

Among 12 analysts covering Abiomed (NASDAQ:ABMD), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Abiomed has $220.0 highest and $80 lowest target. $165.83’s average target is -27.98% below currents $230.27 stock price. Abiomed had 26 analyst reports since August 4, 2015 according to SRatingsIntel. On Tuesday, June 6 the stock rating was maintained by Jefferies with “Buy”. On Monday, October 16 the stock rating was downgraded by BTIG Research to “Neutral”. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Tuesday, August 4 by Benchmark. The firm has “Buy” rating by William Blair given on Thursday, June 8. The firm earned “Buy” rating on Tuesday, August 18 by Sterne Agee CRT. The stock has “Buy” rating by Guggenheim on Wednesday, December 7. The firm has “Buy” rating by Jefferies given on Thursday, September 21. The stock has “Buy” rating by Leerink Swann on Thursday, October 12. As per Thursday, June 29, the company rating was maintained by Jefferies. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Thursday, January 4 by Piper Jaffray.